Cybin is trading at $13.63, up 5.13% after rising from its September 11 close of $12.97.
- No company-specific news release or clinical milestone was reported on September 14, 2026.
- CEO Michael Halstead’s scheduled September 14 H.C. Wainwright fireside chat was announced September 9, but the announcement does not explicitly connect it to the stock move.
- Broader markets are modestly lower, so macro sentiment does not clearly explain Cybin’s gain.